Journal
DIABETES CARE
Volume 33, Issue 10, Pages 2178-2180Publisher
AMER DIABETES ASSOC
DOI: 10.2337/dc10-0494
Keywords
-
Categories
Funding
- Diabetes UK BDA [08/0003702]
- Novo Nordisk
- Asahi Kasei Pharma
- Bayer Healthcare
- Bayer Schering Pharma
- Bristol-Myers Squibb
- GlaxoSmithKline
- Merck
- Merck Serono
- Novartis
- Pfizer
- Sanofi-aventis
- Amylin
- Eli Lilly
Ask authors/readers for more resources
OBJECTIVE - To explore patients' and health professionals experiences of initiating insulin as pan of the Treating To Target in Type 2 Diabetes (4-T) randomized controlled trial. RESEARCH DESIGN AND METHODS - Interviews were conducted with 45 trial participants and 21 health professionals and thematically analyzed. RESULTS - Patients were generally psychologically insulin receptive when approached to participate in the 4-T trial. Their receptiveness arose largely from their personal experiences observing intensifying prior treatments and deteriorating blood glucose control over time, which led them to engage with and accept the idea that their diabetes was progressive. Health professionals also fostered receptiveness by drawing on their clinical experience 10 manage patients' anxieties about initiating insulin. CONCLUSIONS - Previous studies may have overemphasized die problem of psychological insulin resistance and overlooked factors and treatment experiences that may promote insulin receptiveness among type 2 patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available